The model combines estimates of skeletal muscle with routinely collected clinical data and unstructured notes and predicts the individual likelihood of cachexia.

The RAS(ON) inhibitor shrunk tumors in around 60 percent of patients with KRAS G12D mutations, according to a study presented at AACR's annual meeting.

The UK-based company will evaluate BFB-101 in up to five children with hereditary spastic paraplegia type 47 in a Phase I/II trial.

In the study, patients with advanced solid tumors must be HLA-A*02:01 positive and harbor a p53 R175H mutation.

NEW YORK – Seattle-based BrainChild Bio announced Friday that it is advancing its leading drug candidate, a CAR T-cell therapy targeting the immune checkpoint B7-H3 to a registrational trial, to ...

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

Through its Precision Care Companion, McKesson wants to help oncologists bring personalized medicine to their patients ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

During a Q1 earnings call, Merck CEO Rob Davis discussed pipeline diversification plans and effects of tariffs on its ...

The New York-based public benefit corporation is advancing three drug candidates for the extremely rare condition.

Leukemia patients who enroll in LLS's PedAL screening trial and are found to have certain alterations will be directed to receive ziftomenib in a Phase I study.